Related Experiment Videos
Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis
1Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Journal of Biochemistry and Molecular Biology
|December 13, 2005
Summary
Prostaglandin E synthases (PGES) are key enzymes in prostanoid biosynthesis. This review details the distinct roles and regulation of membrane-bound PGES-1, mPGES-2, and cytosolic PGES (cPGES) in inflammation and cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Enzymology
Background:
- Prostanoid biosynthesis involves phospholipase A2, cyclooxygenase (COX), and terminal prostanoid synthases.
- Prostaglandin E synthase (PGES) specifically converts PGH2 to PGE2.
- Multiple PGES forms exist with distinct properties and functions.
Purpose of the Study:
- To review the latest understanding of PGES enzyme expression, regulation, and functions.
- To highlight the distinct characteristics of mPGES-1, mPGES-2, and cPGES.
- To emphasize mPGES-1 as a potential therapeutic target.
Main Methods:
- Literature review of gene targeting studies and enzymatic analyses.
- Analysis of protein localization and expression patterns.
- Functional coupling studies with COX enzymes.
Main Results:
- mPGES-1 is induced by inflammation, downregulated by glucocorticoids, and linked to COX-2; a target for anti-inflammatory/anti-cancer drugs.
- mPGES-2 is a Golgi-associated protein, processed to a cytosolic form, constitutively expressed, and linked to both COX-1 and COX-2.
- cPGES is constitutively expressed and linked to COX-1 for immediate PGE2 production.
Conclusions:
- The three PGES enzymes (mPGES-1, mPGES-2, cPGES) exhibit distinct expression, regulation, and functional coupling.
- Understanding these differences is crucial for developing targeted therapies.
- mPGES-1 emerges as a significant target for anti-inflammatory and anti-cancer drug development.